| 93.085 2.735 (3.03%) | 07-14 11:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 123.18 | 1-year : | 143.88 |
| Resists | First : | 105.47 | Second : | 123.18 |
| Pivot price | 94.9 |
|||
| Supports | First : | 81.34 | Second : | 66.43 |
| MAs | MA(5) : | 91.41 |
MA(20) : | 92.24 |
| MA(100) : | 62.36 |
MA(250) : | 44.71 |
|
| MACD | MACD : | 5.2  |
Signal : | 6.9 |
| %K %D | K(14,3) : | 40.9 |
D(3) : | 41.3 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 105.47 | Low : | 23.29 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TWST ] has closed above bottom band by 41.0%. Bollinger Bands are 23.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 92.9 - 93.43 | 93.43 - 94 |
| Low: | 87.98 - 88.56 | 88.56 - 89.18 |
| Close: | 89.26 - 90.26 | 90.26 - 91.36 |
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Mon, 13 Jul 2026
Twist Bioscience CFO Adam Laponis sells $226,307 in stock By Investing.com - Investing.com South Africa
Mon, 13 Jul 2026
Form 4 Twist Bioscience Corp For: 13 July By Investing.com - Investing.com Canada
Mon, 13 Jul 2026
[Form 4] Twist Bioscience Corp Insider Trading Activity - Stock Titan
Sat, 11 Jul 2026
Is Twist Bioscience’s (TWST) AI Order Momentum Reshaping Its Core Life Sciences Investment Story? - simplywall.st
Sat, 11 Jul 2026
Twist Bioscience (TWST) price target increased by 20.55% to 64.90 - MSN
Thu, 09 Jul 2026
Officer reports multiple common stock sales (NASDAQ: TWST) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 62 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 124.3 (%) |
| Shares Short | 13,950 (K) |
| Shares Short P.Month | 14,900 (K) |
| EPS | -1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.32 |
| Profit Margin | -19.9 % |
| Operating Margin | -35 % |
| Return on Assets (ttm) | -13 % |
| Return on Equity (ttm) | -18.2 % |
| Qtrly Rev. Growth | 19.2 % |
| Gross Profit (p.s.) | 3.42 |
| Sales Per Share | 6.57 |
| EBITDA (p.s.) | -1.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -70.5 |
| PEG Ratio | 0 |
| Price to Book value | 12.71 |
| Price to Sales | 14.15 |
| Price to Cash Flow | -104.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|